A Spotlight on Drug-Induced Vasculitis.

Cocaine Drug-induced ANCA-associated vasculitis Drug-induced vasculitis (DIV) Granulocyte colony-stimulating factor (G-CSF) Hydralazine Immune checkpoint inhibitors (ICIs) Minocycline Propylthiouracil Tumor necrosis factor-α (TNF-α)

Journal

Current rheumatology reports
ISSN: 1534-6307
Titre abrégé: Curr Rheumatol Rep
Pays: United States
ID NLM: 100888970

Informations de publication

Date de publication:
11 2022
Historique:
accepted: 16 08 2022
pubmed: 22 9 2022
medline: 12 10 2022
entrez: 21 9 2022
Statut: ppublish

Résumé

Drug-induced vasculitis (DIV) is a rare form of vasculitis related to the use of various drugs. DIV primarily affects small to medium size vessels, but it can potentially involve vessels of any size. Differentiating between primary systemic vasculitis and DIV can be challenging; however, it is crucial, so that the offending agent can be discontinued promptly. The clinical phenotype of DIV is protean and depends on the size of the affected vessels. It ranges from arthralgias, to an isolated cutaneous rash, to severe single or multi-organ involvement. While withdrawal of the offending drug is the most important step in management, a significant number of patients require immunosuppressive therapy for varying periods of time. DIV can affect any vascular bed size, leading to protean vasculitic syndromes. Increased awareness among general practitioners, specialty, and subspecialty physicians is crucial for early recognition, and withdrawal of drug for better outcomes.

Identifiants

pubmed: 36129631
doi: 10.1007/s11926-022-01088-0
pii: 10.1007/s11926-022-01088-0
doi:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

323-336

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Kinanah Yaseen (K)

Department of Rheumatic and Immunologic Diseases Cleveland Clinic, 9500 Euclid Avenue/A50, Cleveland, OH, 44195, USA. Yaseenk@ccf.org.

Alana Nevares (A)

Division of Rheumatology and Clinical Immunology and Robert Larner, MD, College of Medicine, University of Vermont Medical Center, Burlington, VT, USA.

Hiromichi Tamaki (H)

Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH